We have recently reported that S1P (sphingosine-1-phosphate) differentially regulates cellular Rac activity and cell migration in either a positive or a negative direction via distinct G-proteincoupled receptor subtypes, i.e. S1P 1 /Edg1 (endothelial differentiation gene) and S1P 2 /Edg5 respectively, when each of the S1P receptor subtypes is expressed in CHO (Chinese-hamster ovary) cells. In B16F10 mouse melanoma cells, in which S1P 2 , but not the other S1P receptor subtypes, is endogenously expressed, S1P inhibited cell migration with concomitant inhibition of Rac and stimulation of RhoA in dose-dependent manners. Overexpression of S1P 2 in the melanoma cells resulted in potentiation of S1P inhibition of both Rac and cell migration. In contrast, overexpression of S1P 1 led to stimulation of cell migration, particularly at the lower S1P concentrations. Treatment of B16F10 cells with S1P inhibited lung metastasis 3 weeks after injection into mouse tail veins. Intriguingly, overexpression of S1P 2 greatly potentiated the inhibition of metastasis by S1P, whereas that of S1P 1 resulted in aggravation of metastasis. Suppression of cellular Rac activity by adenovirus-transduced expression of N 17 Rac, but not N 19 RhoA, strongly inhibited cell migration in vitro and lung metastasis in vivo. These results provide the first evidence that G-protein-coupled receptors could participate in the regulation of metastasis, in which ligand-dependent, subtype-specific regulation of the cellular Rac activity is probably critically involved as a mechanism.
INTRODUCTION
S1P (Sphingosine-1-phosphate) is a pleiotropic lysophospholipid mediator that is present in plasma and is released in a large amount from activated platelets [1, 2] . Investigations from several laboratories, including our own, have identified the Edg (endothelial differentiation gene) family of G-protein-coupled receptors for S1P, which include the ubiquitously expressed isotypes S1P 1 /Edg1, S1P 2 /Edg5/AGR16/H218 and S1P 3 /Edg3 [1] [2] [3] [4] [5] [6] . It has been known for a decade that S1P regulates cell motility in either a positive or a negative direction, which appeared to depend upon the cell type tested [2, 3, [7] [8] [9] . Thus S1P inhibits motility of certain types of murine and human tumour cells, including B16 melanoma cells and vascular smooth muscle cells, whereas it acts as a chemoattractant for other cell types, such as vascular endothelial cells. We recently identified S1P 2 as a chemorepellant receptor and the S1P-S1P 2 system as the first example of a receptor-mediated signalling that negatively regulates cellular Rac activity [10] . We and others have also found that S1P 1 and S1P 3 mediate activation of Rac and function as typical chemotactic receptors [10, 11] . These findings strongly suggest that cell-type-dependent, bimodal regulation of cell motility by S1P reflects the S1P-receptor-mediated, subtype-specific biological activities. Differently from Rac, whose activity is regulated in the same direction as cell motility by the S1P signalling system, we and others found that the repulsive receptor S1P 2 [10] , and the Abbreviations used: DH-S1P, dihydrosphingosine-1-phosphate; DMEM, Dulbecco's modified Eagle's medium; Edg, endothelial differentiation gene; GEF, guanine nucleotide-exchange factor; i.p., intraperitoneal; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium, inner salt; S1P, sphingosine-1-phosphate. 1 To whom correspondence should be addressed (e-mail ytakuwa@med.kanazawa-u.ac.jp).
attractive receptor S1P 3 [10, 11] , similarly mediated stimulation of cellular RhoA activity. S1P did not affect cellular Cdc42 activity through either of the S1P receptor subtypes. In addition, the expression of dominant negative mutants N 17 Rac or N 17 Cdc42, but not N 19 RhoA, inhibited cell migration [10] . These observations strongly suggest that cellular Rac and Cdc42 activities, but not necessarily RhoA activity, are required for cell motility, and that S1P receptor subtype-specific bimodal regulation of Rac activity is involved as a mechanism for the S1P-elicited distinct regulation of cell motility [3] .
Metastasis is a temporo-spatially arranged multistep phenomenon that includes cell motility, extracellular-material degradation and proliferation. Previous studies [12] [13] [14] [15] [16] [17] have implicated Rho family GTPases and their activator GEFs (guanine nucleotide-exchange factors) in transformation and invasive phenotypes. However, most of these studies were performed in in vitro cultured cell systems, and their precise roles in development of metastasis in vivo have remained elusive thus far.
Our observations on S1P-receptor-mediated, subtype-specific bimodal regulation of Rac and cell migration prompted us to examine the possible involvement of the S1P signalling system in the regulation of metastasis in vivo. By employing a wellcharacterized mouse tail vein injection model of haematogenous metastasis, we found that S1P receptors could positively and negatively regulate metastasis in receptor-subtype-specific, liganddependent manners. We also adopted adenovirus-mediated transient expression of N 17 Rac to investigate whether indeed Rac activity in tumour cells is required for the development of metastasis.
EXPERIMENTAL

Materials
S1P and DH-S1P (dihydrosphingosine-1-phosphate) were obtained from Biomol (Plymouth Meeting, PA, U.S.A.). Sphingosine was purchased from Avanti (Birmingham, AL, U.S.A.). These lipids were dissolved in DMSO to 2 × 10 −3 M, divided into aliquots and stored at − 80
• C. Final solvent concentrations did not exceed 0.1 % (v/v). Fatty-acid-free BSA was obtained from Sigma (St. Louis, MO, U.S.A.). Mouse monoclonal anti-Rac and anti-RhoA antibodies and a goat polyclonal anti-RhoC antibody were purchased from Upstate Biotechnology (Charlottesville, VA, U.S.A.) and Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.) respectively.
Cells, plasmids and adenoviruses
B16 (B16F10) cells, a gift from Dr T. Irimura (Graduate School of Pharmaceutical Sciences, University of Tokyo), were grown in DMEM (Dulbecco's modified Eagle's medium) supplemented with 10 % (v/v) foetal calf serum (Equitech-Bio, Ingram, TX, U.S.A.) and antibiotics. The cDNAs of S1P 1 and S1P 2 and adenoviruses encoding dominant-negative mutants N 17 Rac, N 19 RhoA or LacZ were described previously [10, [18] [19] [20] . B16 cells were infected with adenoviruses at an MOI (multiplicity of infection) of approx. 100, as described in [10] . This condition conferred expression of LacZ as a marker gene in nearly 100 % of infected cells 48-72 h after infection, when the expression of transduced gene products was maximal. Therefore adenovirusinfected cells were harvested 48 h after infection and were subjected to in vivo and in vitro assays throughout the present study. To obtain B16 cell clones that stably overexpressed either S1P 1 or S1P 2 , a parent B16F10 clone that had been obtained by limiting dilution was co-transfected with each of the S1P-receptor-expression vectors, or the empty vector, together with an expression vector of the neomycin resistance gene (pKM3) using LIPOFECTAMINE TM (Invitrogen, Carlsbad, CA, U.S.A.), and were selected in the presence of 1 mg/ml G418. The receptor-subtypeoverexpressing clones, B16-S1P 1 -1 and -9, and B16-S1P 2 -7 and -14 were identified by Northern blot analysis.
Northern blotting
Total RNA (10 µg), prepared as described previously [21] was analysed for expression of mRNAs of S1P receptors and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) by Northern blotting as described in [21] . The cDNA probes employed were described previously [10, [18] [19] [20] .
Lung metastasis assay
B16 cells were harvested by trypsinization, suspended at a density of 1 × 10 6 cells/ml in DMEM containing 0.1 % (v/v) fatty-acidfree BSA, and incubated with S1P, other lipids or 0.1 % (v/v) DMSO (vehicle control) for 5 min at room temperature (25 • C). The cells were washed and resuspended in Hanks' solution at a density of 1 × 10 6 cells/ml at 4 • C and a 100 µl cell suspension was injected into the lateral tail veins of 6-week-old male C57BL/6 mice. In some experiments, mice were injected daily with 10 µg of S1P or 0.1 % (v/v) DMSO in a volume of 100 µl through the i.p. (intraperitoneal) route for 3 weeks. On the first day of this set of experiments, S1P was i.p. injected 30 min before the tail-vein injection of B16 cells. In a different set of experiments, B16 cells were infected with adenoviruses, as described above, and were harvested after 48 h and subjected to a lung metastasis assay. At this time point, viability of adenovirusinfected cells was consistently > 95 %. Actin cytoskeletal changes in N 19 RhoA-expressing cells at the time of injection were evaluated by phalloidin staining, as described previously [18, 20] . At 3 weeks after injection, mice were killed by an excess amount of pentobarbital, and the lungs were excised, rinsed in Dulbecco's PBS, and fixed overnight in Bouin's solution [22, 23] . The metastatic colonies were easily identified by the naked eye as clearly demarcated black or white nodules in the background of normal lung tissue, which stained deep yellow. The numbers of metastatic nodules present over the entire surface of the five lobes of the lung were counted under a dissecting microscope at a magnification of × 10 by an examiner to whom the identity of the sample was not notified. Nodule counting was performed three times per sample and the mean value was determined. All animals received humane care in compliance with our institutional guidelines.
Proliferation assays
To evaluate the ability of the cells used for lung metastasis assays to proliferate, a portion from each cell-treatment group was saved, and was seeded at 4 × 10 4 cells/well in 2 ml of growth medium in 6-well plates. The cells in each well were maintained in exactly the same way at subconfluent states with routine subcultures every 3 or 4 days throughout the metastasis assay period (21 days). On days 3, 7, 14 and 21 after plating, cells were trypsinized and viable cells were counted in a haemocytometer by Trypan-Blue exclusion. In a different set of experiments, cell proliferation in the presence or absence of S1P was evaluated by using an MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium, inner salt] cell proliferation assay (Promega) [24] . MTS was added to each of 96 wells 72 h after plating, and the cells were incubated for a further 4 h. The numbers of living cells were determined by measuring attenuance at 490 nm using a 96-well microplate reader (Bio-Rad Model 3550; Hercules, CA, U.S.A.).
Trans-well migration assay, and Rho, Rac and Cdc42 pull-down assays
Haptotactic motility of B16F10 cells was measured in a modified Boyden chamber as described previously [10, 18] with a polycarbonate filter (8 µm diameter pores) (Neuroprobe, Cabin John, MA, U.S.A.), the lower side of which was coated with 10 µg/ml fibronectin (Sigma). The cells were suspended at 1 × 10 6 cells/ml in DMEM containing 0.1 % (v/v) fatty-acidfree BSA and 300 µl of the cell suspension was loaded into the upper well and allowed to migrate across the porous filter for 4 h at 37
• C in a tissue culture incubator, in the presence or absence of S1P in the lower well. In some experiments, adenovirus-infected cells were harvested 48 h after infection and were subjected to migration assays. At the end of the assay, the filter was disassembled from the chambers and the cells that remained attached to both sides of the filter were fixed with methanol. After staining of the cells by using a Diff-Quick staining kit (International Reagents Corp., Kobe, Japan), as described previously [10, 18] , the cells attached to the upper side of the filter were wiped away, and the number of cells that migrated to the lower side of the filter was determined by measuring attenuance Total RNAs from mouse brain, spleen and rat aortic vascular smooth muscle cells (VSMC) as positive controls for S1P 3 , S1P 4 and S1P 5 transcripts were also analysed. The other clones, B16-S1P 1 -9 and B16-S1P 2 -14, showed similar results.
at 595 nm using the Model 3550 96-well microplate reader. Determinations of cellular amounts of GTP-bound, active forms of Rac, Cdc42 and RhoA by pull-down-assay techniques were described in detail previously [10, 18, 27] . A portion (1/200 for Rac and RhoA, and 1/30 for Cdc42) of cell extracts was also analysed by Western blotting for the amounts of total Rac and RhoA. The bands of GTP-Rac and GTP-RhoA were densitometrically quantified and values were expressed as fold increases over the basal unstimulated values (= 1) [10] .
Statistics
The data are presented as means + − S.E.M. The statistical significance of differences between the two groups was determined by Student's t test, whereas multiple comparisons were analysed by Duncan's test.
RESULTS
Northern blot analysis revealed that naïve B16F10 cells showed a moderate level of endogenous S1P 2 mRNA. The expression level of endogenous S1P 2 mRNA remained relatively constant in the cells that overexpressed either S1P 1 or S1P 2 , or in vectorcontrol cells (Figure 1) . None of these cell types expressed detectable amount of the other S1P receptor subtypes (Figure 1) .
We first examined and compared the effects of S1P on haptotactic cell migration in vitro (Figure 2) . S1P, when present in the lower well of a Boyden chamber, inhibited the migration of vectorcontrol B16 cells in a dose-dependent manner, with 10, 30 and Vector-control B16F10 cells and the B16F10 clones that overexpress S1P 1 (clone B16-S1P 1 -1) or S1P 2 (clone B16-S1P 2 -7) were allowed to migrate across the porous membrane in the presence or absence of the indicated concentrations of S1P in the lower wells for 4 h. Results are means + − S.E.M. (n = 3). *, P < 0.05; ***, P < 0.001, compared with the vehicle (DMSO) control. The other clones showed similar results.
56 % inhibition at 10 −9 , 10 −8 and 10 −7 M respectively, as compared with the basal value in the absence of S1P (Figure 2 ). Similar results were observed for naïve B16 cells. S1P 2 -overexpressing cells (clone B16-S1P 2 -7) were more sensitive to S1P; S1P at 10 −9 M induced 65 % inhibition of cell migration. In sharp contrast, S1P did not inhibit the migration of S1P 1 -overexpressing cells (clone B16-S1P 1 -1), except at the highest concentration examined, and it even stimulated migration at lower concentrations (10 −9 M and 10 −8 M). The enhancement of inhibition of cell migration by overexpression of S1P 2 , and the attenuation by that of S1P 1 , were also observed for the other B16 clones (B16-S1P 1 -9 and B16-S1P 2 -14) (results not shown).
We next studied the effects of S1P on cellular activity of Rac in these B16 cell types ( Figure 3A) The expression level of total Rac protein or the basal level of GTP-bound active form of Rac (GTP-Rac) in the absence of S1P were not affected by overexpression of either S1P 1 or S1P 2 . S1P induced dosedependent reductions in the amount of GTP-Rac in vectortransfected B16F10 cells, with a 35 % reduction at 10 −8 M of S1P ( Figure 3A) . The suppression in the GTP-Rac level persisted for < 10 min (results not shown). Similar results were obtained for naïve B16F10 cells. S1P 2 -overexpressing cells were more sensitive to S1P inhibition of cellular Rac activity; in this cell type, 10 −9 M of S1P induced a significant 40 % reduction in the level of GTP-Rac. In contrast, overexpression of S1P 1 rendered the cells resistant to S1P inhibition of Rac, and S1P at 10 −8 M did not inhibit GTP-loading of Rac. The expression level of total RhoA protein and the basal RhoA activity were comparable among the different B16 cell types ( Figure 3B ). S1P increased the amounts of GTP-RhoA in all of the three B16 cell types ( Figure 3B ). We also tried to determine the activity of RhoC [25] ; however, its expression in B16 cells was below a detectable level. We measured the activity of Cdc42 in B16 cells and found that S1P at 10 −7 M did not affect Cdc42 activity for at least 30 min in naïve B16F10 cells ( Figure 3C ) or the vector-control cells.
We then examined whether or not S1P could modulate pulmonary metastasis of B16F10 cells (Figure 4) . We found that a single and transient treatment of naïve B16F10 cells with S1P (10 −7 M) for 5 min immediately before the tail vein injection resulted in a 40 % decrease in the number of pulmonary metastatic nodules which were examined 3 weeks later ( Figure 4A ). Daily i.p. injection of S1P (10 µg/day) into mice, with the first S1P bolus given 30 min before injection of untreated B16 cells, also caused a similar extent of inhibition on pulmonary metastasis ( Figure 4A ). The combination of both treatments caused a larger decrease (by 60 %) in metastasis than either managed alone. We also examined the effects of DH-S1P, which is a less potent agonist for S1P 2 [10, 26] , and sphingosine, which is not an agonist for the S1P receptors, on the melanoma cell metastasis ( Figure 4B ). The effect of DH-S1P was much limited compared with S1P, and sphingosine was essentially ineffective, consistent with the receptor-mediated actions of S1P. Shown in Figure 4 (C) are the effects of pre-treatment with various concentrations of S1P on pulmonary metastasis of B16F10 vector-control cells and the cells that overexpress either S1P 1 or S1P 2 . In vector-control cells, S1P at 10 −7 M, but not at lower concentrations, caused a significant inhibition (56 %) of the metastatic nodule formation, consistent with the results obtained in naïve B16 cells (Figures 4A and 4B) . We found that S1P 2 -overexpressing cells were approx. two orders of magnitude more sensitive to S1P inhibition of metastasis compared with the vector control; pre-treatment with S1P at 10 −9 M resulted in a 53 % inhibition of metastasis, with a maximal 81 % inhibition at 10 −7 M of S1P. Another S1P 2 -overexpressing clone (B16-S1P 2 -14) also showed augmented inhibition of metastasis by S1P; the numbers of metastatic nodules after S1P pre-treatment at 10 −9 M and 10 −7 M were 57 + − 5 % and 24 + − 4 % of the vehicle control respectively (n = 8). The results contrast sharply with those obtained with S1P 1 -overexpressing cells, in which S1P at 10 −9 M and 10 −8 M stimulated pulmonary metastasis markedly ( Figure 4C ). We observed a similar stimulatory effect of S1P on metastasis in a different S1P 1 -overexpressing clone (B16-S1P 1 -9); the numbers of metastatic nodules after S1P treatment at 10 −9 M were 206 + − 11 % of the vehicle control (n = 8). Without S1P pre-treatment, there was no difference in the numbers of metastatic nodules between S1P 1 -or S1P 2 -overexpressing B16 cells and vector-control cells. These results suggest that S1P 2 is the receptor subtype responsible for the S1P inhibition of metastasis, whereas S1P 1 mediates S1P stimulation, rather than inhibition, of metastasis. Blunting of the metastasis-stimulatory effect of S1P at high concentrations in S1P 1 -expressing cells may reflect counteractions between exogenously expressed S1P 1 and endogenous S1P 2 as observed in in vitro systems [27] . We adopted adenovirus-transduced expression of a dominantnegative Rac, N 17 Rac, to evaluate the roles of endogenous Rac activity in tumour cells in developing metastasis. We infected naïve B16 cells with adenoviruses encoding either N 17 Rac, N 19 RhoA or β-galactosidase (LacZ). After 48 h, when the expression levels were maximal ( Figure 5A ), the cells were harvested and were subjected to the metastasis assay ( Figure 5D ), as well as migration ( Figure 5B ) and proliferation ( Figure 5C ) assays. We observed that the expression of N 17 Rac, but not N 19 RhoA, markedly (by 76 %) inhibited trans-well migration of B16 cells ( Figure 5B ). The results indicate that Rac is required for migration of B16F10 cells, and that adenovirus-mediated expression of N 17 Rac effectively inhibits endogenous Rac activity. In addition, we found that the expression of N 17 Cdc42 also substantially inhibited cell migration in vitro as compared with the LacZ control ( Figure 5B ), although S1P did not affect cellular Cdc42 activity ( Figure 3C ). These observations suggest that the basal activity of Cdc42 is necessary for haptotactic cell motility of B16 cells.
As shown in Figure 5 (D), the expression of N 17 Rac caused a 74 % decrease in the number of metastatic nodules as compared with the LacZ control, providing compelling in vivo evidence that cellular Rac activity is required for metastasis. The expression of N 19 RhoA, which inhibited S1P-induced actin stress-fibre formation in B16 cells, caused a slight, although not significant, inhibition of metastasis formation.
To evaluate critically a possibility that the inhibition of metastasis by N 17 Rac expression had been the result of cell death,
Figure 4 S1P inhibits pulmonary metastasis of B16F10 cells
(A) Numbers of pulmonary metastatic nodules formed 3 weeks after injection of naïve B16F10 cells into tail veins. S1P was either added to the cells for 5 min just before injection (pre-treatment at a final concentration of 10 −7 M), and/or administered to mice daily (10 µg/day) via the i.p. route. (B) Pre-treatment for 5 min with the weak S1P agonist DH-S1P (10 −7 M), but not sphingosine (Sph), modestly inhibited lung metastasis. (C) S1P 2 overexpression augments S1P inhibition of metastasis, whereas that of S1P 1 aggravates it. Stable B16 clones, B16-S1P 1 -1 and B16-S1P 2 -7, and vector-transfected B16 cells were pre-treated with S1P at the indicated concentrations for 5 min before injection into mice. Additional clones showed similar receptor-subtype-specific, ligand-dependent responses (see text). Results are means + − S.E.M. (A) and (C), n = 8; (B), n = 5. *, P < 0.05; **, P < 0.1; ***, P < 0.001, compared with the vehicle (DMSO) control.
we plated a portion of the adenovirus-transduced cell populations employed for metastasis assays and examined their proliferation in vitro by counting numbers of the cells at 3, 7, 14 and 21 days after the tail vein injection. We found that the number of the cells relative to the LacZ control was decreased by 18 % and 15 % in the cells transduced with adenoviruses encoding N 17 Rac and N 19 RhoA respectively by day 3 ( Figure 5C ). However, there was no additional reduction in the cell number thereafter, consistent with the transient nature of the adenovirus-transduced expression system. The same extent (18 %) of a modest inhibition of cell proliferation during the first 3 days for N 17 Rac-expressing cells was also observed when the MTS proliferation assay was adopted. The results strongly suggest that a mechanism other than inhibition of proliferation is involved as a major mechanism for inhibition of metastasis.
DISCUSSION
The present study demonstrates for the first time that S1P inhibited metastasis of B16F10 melanoma cells in S1P-receptor-isoformspecific, ligand-dependent manners ( Figures 4A-4C ) in the tail vein injection model. We have also demonstrated in the present study that inhibition of endogenous Rac activity in mouse B16 melanoma cells by adenovirus-mediated transient expression of N 17 Rac potently inhibited metastasis ( Figure 5D ). Several lines of evidence obtained in the present study indicate that S1P 2 is responsible for mediating S1P inhibition of metastasis. They include (i) naïve B16 cells detectably expressed mRNA of S1P 2 , but not the other members of the S1P receptors ( Figure 1) ; (ii) the overexpression of S1P 2 strongly potentiated S1P inhibition of metastasis, compared with vector-control cells, whereas that of S1P 1 resulted in aggravation of metastasis in response to S1P ( Figure 4) ; (iii) consistent with the results on metastasis, the overexpression of S1P 2 , but not S1P 1 , strengthened the S1P inhibition of migration ( Figure 2) ; (iv) DH-S1P, which is less potent as an agonist for S1P 2 than S1P by at least one order of magnitude [26] , was less effective in inhibiting metastasis compared with S1P in naïve B16F10 cells, whereas sphingosine, which is not an agonist for S1P receptors, was totally ineffective ( Figure 4B) ; (v) the overexpression of S1P 2 , but not S1P 1 , potentiated S1P inhibition of cellular Rac activity ( Figure 3A) , which is essential for the processes of cell migration and metastasis ( Figure 5D ), like S1P inhibition of metastasis and cell motility.
Since Rac is essential for metastatic process ( Figure 5D ), it is reasonable to consider that S1P inhibition of metastasis is mediated at least in part through S1P 2 -selective, receptor-mediated negative regulation of Rac activity. We found in the present study that pre-treatment with S1P for 5 min was sufficient for reducing pulmonary metastasis formation (Figures 4A-4C) . With this regard, we observed that S1P-induced, S1P 2 -mediated suppression of cellular Rac activity was sustained for > 10 min in B16 cells, as well as in other cell types [10, 18] . These observations suggest that a transient change in the cellular Rac activity serves as a crucial signal for such long-term biological responses as metastasis formation in the tail vein injection model. A previous study demonstrated that injected B16 cells formed microemboli in pulmonary capillary beds within several minutes of intravenous injection, and that this process is critical for later stages of metastasis to proceed [28] . It is suggested that very early events in the process of haematogenous metastasis, including microembolus formation, is dependent upon cellular Rac activity. We are now investigating this possibility.
The present results, however, do not exclude roles for Rac in the following stages of metastasis, in which tumour cells invade and proliferate. In support of this latter possibility, we observed that the expression of N 17 Rac in B16F10 cells markedly inhibited migration ( Figure 5B ) and invasion [29] through Matrigel, and also suppressed proliferation, although to a much limited extent ( Figure 5C ). In addition, we found that daily i.p. administration of S1P, in combination with S1P pre-treatment of the tumour cells before intravenous injection, caused an additional reduction in metastasis ( Figure 4A ), suggesting that late stages of metastasis development are also modulated by S1P. Thus Rac may be necessary for multiple processes of metastasis. To explore roles for Rac in more depth in the late stages of metastasis, different experimental designs would be required, such as inducible expression of N 17 Rac and delayed administration of S1P in future studies. During the final stage of the preparation of the present paper, it was reported that stable overexpression of N 17 Rac in rat mammary adenocarcinoma cells resulted in reduced metastasis formation [30] . However, inhibitory effects of a receptor ligand on metastasis and cellular Rac activity were not addressed. It was also reported previously that stable overexpression of a constitutively active form of Rac in NIH3T3 fibroblasts resulted in stimulation of metastasis [31] .
In the present study, we found that the expression of N 19 Rho slightly inhibited metastasis ( Figure 5D ), without inhibiting migration ( Figure 5B ). It is possible that a modest (15 %) inhibition of proliferation by transient N 19 RhoA expression ( Figure 5C ) could be responsible, at least in part, for the observed slight inhibition of metastasis. However, we also found that the C3 toxin, which exerted a stronger inhibition of Rho than N 19 Rho expression, as estimated by its inhibitory effect on precipitated RhoA, failed to inhibit migration, but significantly inhibited metastasis. These latter observations indicate that, although migration may not require RhoA, metastasis requires RhoA activity in tumour cells in vivo, which is consistent with the suggested role for Rho in metastasis in previous reports [30, 31] . With respect to this, it is of note that S1P, especially at its lower concentrations, stimulated metastasis of S1P 1 -overexpressing B16 cells ( Figure 4C ). This might have resulted from RhoA stimulation without Rac inhibition in this cell type, which was most likely brought about by the counteraction of S1P 2 -mediated Rac inhibitory signal by S1P 1 -mediated Rac stimulatory signal. Precise roles of RhoA in each of the multistep processes of metastasis should be elucidated in future studies.
It is also the subject of future work to determine whether or not Cdc42 is required for metastasis. In the present study, we observed that S1P was without effect on cellular Cdc42 activity ( Figure 3C ). We also found that the expression of N 17 Cdc42 inhibited haptotactic cell motility ( Figure 5B ). These observations together may suggest that the basal activity of Cdc42 is required for migration of B16 cells. Alternatively, the expression of N 17 Cdc42 might have inhibited a GEF(s) for Rac, resulting in inhibition of Rac activation and thereby of migration, since several GEFs are known to act on both Rac and Cdc42 [32] .
In the tail vein injection model, we failed to detect any change in the extent of metastasis of B16 cells without S1P pretreatment by overexpression of either S1P 1 or S1P 2 . It has been reported that S1P is present in the circulation at a concentration of approx. 200 nM in forms mostly bound to plasma proteins, which give rise to 7 % in man [33, 34] . Since the present results were obtained in the presence of 0.1 % (v/v) BSA in medium for the treatment of B16 cells, it is reasonable to consider that much higher concentrations of S1P would have been required if 7 % plasma proteins were present in the medium. Although the free S1P concentration in the mouse plasma is not known at present, it is likely to be below the threshold level that would be required to affect metastasis of intravenously injected B16 cell clones in the present experimental design, in which plasma S1P must act on injected cells before they reach pulmonary microvasculature where critical initial events of metastasis take place. It is suggested that, in a living animal, the sites of platelet activation, which often associate with inflammation and immune responses, probably face higher concentrations of S1P than plasma, as platelets reportedly release a large amount of S1P upon activation [33] . It is a possibility that deserves future study that increased levels of S1P at the site of tumourhost interaction would affect motility of tumour cells through S1P-receptor-isotype-specific manners, resulting in positive or negative regulation of tumour cell invasion, extravasation and metastasis. In addition to platelets, a variety of cells and tissues are potential sources of extracellular S1P, as sphingosine kinase, the S1P synthesizing enzyme, is widely expressed [35] . In addition, it is reported that cytokines such as TNFα (tumour necrosis factor α) are capable of stimulating sphingosine kinase activity [36] . On the other hand, in light of the fact that the S1P receptor subtypes such as S1P 1 , S1P 2 and S1P 3 are ubiquitously expressed [1, [3] [4] [5] , it is not surprising to find S1P receptor mRNA expression in a variety of tumour cell types of different tissue origins. (H. Yamaguchi and Y. Takuwa, unpublished work) These composite observations raise an intriguing possibility of targeting tumour cell Rac activity through endogenous G-protein-coupled S1P receptors. Development of S1P 2 -selective agonists and S1P 1 -specific antagonists may enable tailor-made medical intervention against metastasis.
